Clinical Trial Update: Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib maintenance with pembrolizumab and bevacizumab in BRCA wild-type, platinum-sensitive recurrent ovarian cancer are currently en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yonsei University | Conditions: Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION